MicroRNA News and Research

RSS
In genetics, microRNAs (miRNA) are single-stranded RNA molecules of 21-23 nucleotides in length, which regulate gene expression. miRNAs are encoded by genes from whose DNA they are transcribed but miRNAs are not translated into protein (i.e. they are non-coding RNAs); instead each primary transcript (a pri-miRNA) is processed into a short stem-loop structure called a pre-miRNA and finally into a functional miRNA. Mature miRNA molecules are partially complementary to one or more messenger RNA (mRNA) molecules, and their main function is to down-regulate gene expression.
Asuragen enters into research agreements to develop microRNA-based diagnostic test

Asuragen enters into research agreements to develop microRNA-based diagnostic test

USPTO allows claims to Rosetta Genomics' two microRNA related patent applications

USPTO allows claims to Rosetta Genomics' two microRNA related patent applications

Global market for oncology drugs is forecast to reach $80 billion by 2050

Global market for oncology drugs is forecast to reach $80 billion by 2050

Prometheus Laboratories executes commercialization agreement with Novartis

Prometheus Laboratories executes commercialization agreement with Novartis

Texas to invest $4.5 mn in cancer research at UT Health Science Center

Texas to invest $4.5 mn in cancer research at UT Health Science Center

Global health community to be engaged in using resources of GSK and Alnylam IP Pool

Global health community to be engaged in using resources of GSK and Alnylam IP Pool

New LNP compositions that improve systemic delivery of RNAi therapeutics discovered

New LNP compositions that improve systemic delivery of RNAi therapeutics discovered

Alnylam Pharmaceuticals presents data on multiple therapeutic programs at RNAi Symposium

Alnylam Pharmaceuticals presents data on multiple therapeutic programs at RNAi Symposium

Regulus Therapeutics presents new data on oncology, immune disease and HCV therapeutic programs

Regulus Therapeutics presents new data on oncology, immune disease and HCV therapeutic programs

Researchers identify ways to predict patients with small-cell lung cancer

Researchers identify ways to predict patients with small-cell lung cancer

miRagen Therapeutics establishes SAB

miRagen Therapeutics establishes SAB

Isis Pharmaceuticals adds ISIS-APOCIIIRx to its development pipeline to treat TG

Isis Pharmaceuticals adds ISIS-APOCIIIRx to its development pipeline to treat TG

Mirna Therapeutics receives ETF award to develop miRNA therapeutics for multiple cancers

Mirna Therapeutics receives ETF award to develop miRNA therapeutics for multiple cancers

Key mechanism for systemic delivery of RNAi therapeutics using LNPs discovered

Key mechanism for systemic delivery of RNAi therapeutics using LNPs discovered

Alnylam Pharmaceuticals receives payment from Roche to initiate pre-IND studies for RNAi therapeutics

Alnylam Pharmaceuticals receives payment from Roche to initiate pre-IND studies for RNAi therapeutics

Advances in development of “lipidoid” formulations for systemic delivery of RNAi therapeutics

Advances in development of “lipidoid” formulations for systemic delivery of RNAi therapeutics

Tel Aviv University's new Genome Analyzer fuels research dreams and tomorrow's cures

Tel Aviv University's new Genome Analyzer fuels research dreams and tomorrow's cures

OncoGenex Pharmaceuticals to pay Isis Pharmaceuticals $10M for license of OGX-011 to Teva Pharmaceutical Industries

OncoGenex Pharmaceuticals to pay Isis Pharmaceuticals $10M for license of OGX-011 to Teva Pharmaceutical Industries

Rosetta Genomics announces third-quarter 2009 financial results

Rosetta Genomics announces third-quarter 2009 financial results

Regulus Therapeutics wins exclusive rights to modulate microRNAs

Regulus Therapeutics wins exclusive rights to modulate microRNAs

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.